Key result
ACE ID genotype links to ~380% worse bladder cancer prognosis despite no overall risk association.
Why the study?
Bladder cancer is one of the most frequent urinary tract malignancies, but the association between ACE I/D polymorphism (rs1799752) and bladder cancer risk in Egyptian patients was unclear.
Is the ACE I/D polymorphism associated with bladder cancer risk and aggressiveness in Egyptian patients?
Case-Control (n=190)
Is the ACE I/D polymorphism associated with bladder cancer risk and aggressiveness in Egyptian patients?
The ACE I/D polymorphism (ID genotype) is associated with poor prognosis and tumor aggressiveness in Egyptian patients with bladder cancer, though not with overall cancer risk.
Answers are grounded in this paper and cite their sources.
ACE I/D testing should not inform bladder cancer risk assessment; leaves open its role in Egyptian patients pending validation.
Background Bladder cancer (BC) is one of the most frequent malignancies of the urinary tract. Objectives This study aimed to investigate the association between angiotensin-converting enzyme (ACE) I/D polymorphism (rs1799752) and bladder cancer risk in Egyptian patients. Design and methods Bladder cancer cases (n = 140) were diagnosed based on cystoscopy and confirmed by histopathological examination of biopsies. Fifty sex- and age-matched healthy individuals served as controls. Peripheral blood was used to extract the genomic DNA, and the ACE I/D (rs1799752) polymorphism was genotyped using polymerase chain reaction (PCR). Results Genotype frequencies were comparable between groups (II:12% vs. 11.4%, ID: 76% vs. 74%, and DD: 12% vs14.3% in control and BC patients, respectively), with no significant difference in allele or genotype distributions (co-dominant model DD vs. II: OR 1.25, 95%CI 0.34–4.63, p = 0.751). However, within the patient group, the heterozygous genotype (ID) was significantly more prevalent in high grade tumors (P = 0.0177), muscle-invasive BC (MIBC, p = 0.0042), and poor prognosis cases (high grade + MIBC, P < 0.0017). The over-dominant model (ID vs. II + DD) showed a strong association with poor prognosis (OR = 4.8, 95%CI 1.96–11.78, p < 0.001). A trend toward higher ID frequency that did not reach statistical significance was observed in advanced stages (T3/T4, p = 0.058). Conclusion The ID genotype is strongly linked to the carcinogenesis of BC and with the poor prognosis, indicating its possible role as a predictive biomarker for risk assessment and progression in this population.
No takes yet. Share an insight, caveat, or question.
Atia et al. (2026) conducted a case-control in Bladder cancer (n=190). ACE I/D (rs1799752) polymorphism vs. Healthy controls was evaluated on Bladder cancer risk (OR 1.25, 95% CI 0.34-4.63, p=0.751). The ACE I/D polymorphism was not associated with bladder cancer risk, but the ID genotype was strongly linked to poor prognosis.
Synapse has enriched 10 related papers. Consider them for comparative context: